Aethlon Medical (NASDAQ:AEMD – Get Free Report) is expected to release its Q4 2025 earnings data before the market opens on Thursday, June 26th. Analysts expect Aethlon Medical to post earnings of ($0.13) per share for the quarter.
Aethlon Medical Stock Down 1.7%
NASDAQ:AEMD opened at $1.74 on Thursday. Aethlon Medical has a 52 week low of $1.66 and a 52 week high of $8.44. The stock has a market capitalization of $3.50 million, a price-to-earnings ratio of -0.14 and a beta of 1.89. The firm has a 50 day moving average of $2.84 and a 200 day moving average of $3.82.
Wall Street Analysts Forecast Growth
AEMD has been the topic of a number of research reports. Wall Street Zen initiated coverage on shares of Aethlon Medical in a research note on Thursday, May 15th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Featured Articles
- Five stocks we like better than Aethlon Medical
- Technology Stocks Explained: Here’s What to Know About Tech
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
